176 related articles for article (PubMed ID: 32132864)
1. Inverse Association between Metformin and Amiodarone-Associated Extracardiac Adverse Events.
Kinoshita S; Hosomi K; Yokoyama S; Takada M
Int J Med Sci; 2020; 17(3):302-309. PubMed ID: 32132864
[No Abstract] [Full Text] [Related]
2. Dipeptidyl Peptidase-4 Inhibitor-Associated Risk of Bleeding: An Evaluation of Reported Adverse Events.
Rahman MM; Scalese MJ; Hansen RA
Ann Pharmacother; 2017 Jul; 51(7):563-569. PubMed ID: 28166651
[TBL] [Abstract][Full Text] [Related]
3. Inverse association between DPP-4 inhibitor use and fracture in older adults: A disproportionality analysis of the FAERS and JADER.
Ohyama K; Okamoto T; Hori Y
Int J Clin Pharmacol Ther; 2023 Jan; 61(1):16-23. PubMed ID: 36366967
[TBL] [Abstract][Full Text] [Related]
4. Association between dipeptidyl peptidase-4 inhibitor and aspiration pneumonia: disproportionality analysis using the spontaneous reporting system in Japan.
Noguchi Y; Esaki H; Murayama A; Sugioka M; Koyama A; Tachi T; Teramachi H
Eur J Clin Pharmacol; 2020 Feb; 76(2):299-304. PubMed ID: 31822955
[TBL] [Abstract][Full Text] [Related]
5. Time-to-onset analysis of amiodarone-associated thyroid dysfunction.
Kinoshita S; Hosomi K; Yokoyama S; Takada M
J Clin Pharm Ther; 2020 Feb; 45(1):65-71. PubMed ID: 31400296
[TBL] [Abstract][Full Text] [Related]
6. Association of gynecomastia with antidiabetic medications in older adults: Data mining from different national pharmacovigilance databases.
Ohyama K; Tanaka H; Shindo J; Shibayama M; Iwata M; Hori Y
Int J Clin Pharmacol Ther; 2022 Jan; 60(1):24-31. PubMed ID: 34622771
[TBL] [Abstract][Full Text] [Related]
7. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
8. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
9. Use of Spontaneous Reporting Systems to Detect Host-Medication Interactions: Sex Differences in Oral Anti-Diabetic Drug-Associated Myocardial Infarction.
Wang SH; Chen WJ; Hsu LY; Chien KL; Wu CS
J Am Heart Assoc; 2018 Nov; 7(22):e008959. PubMed ID: 30571494
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
Raschi E; Poluzzi E; Koci A; Antonazzo IC; Marchesini G; De Ponti F
Nutr Metab Cardiovasc Dis; 2016 May; 26(5):380-6. PubMed ID: 27067162
[TBL] [Abstract][Full Text] [Related]
11. A pharmacovigilance study of the association between tetracyclines and hepatotoxicity based on Food and Drug Administration adverse event reporting system data.
Wei C; Liu Y; Jiang A; Wu B
Int J Clin Pharm; 2022 Jun; 44(3):709-716. PubMed ID: 35364753
[TBL] [Abstract][Full Text] [Related]
12. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
13. Agranulocytosis and secondary infection related to JAK inhibitors and IL-6 receptor blockers: a disproportionality analysis using the US Food and drug administration adverse event reporting system.
Wei C; Yin W; Hu T; Zhang J; Dan H; Wu B
Front Pharmacol; 2023; 14():1323240. PubMed ID: 38264533
[No Abstract] [Full Text] [Related]
14. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
[TBL] [Abstract][Full Text] [Related]
15. Signal Detection for Cardiovascular Adverse Events of DPP-4 Inhibitors Using the Korea Adverse Event Reporting System Database, 2008-2016.
Yi H; Lee JH; Shin JY
Yonsei Med J; 2019 Feb; 60(2):200-207. PubMed ID: 30666842
[TBL] [Abstract][Full Text] [Related]
16. Association Between Antidiabetic Drugs and Delirium: A Study Based on the Adverse Drug Event Reporting Database in Japan.
Ishibashi Y; Sogawa R; Ogata K; Matsuoka A; Yamada H; Murakawa-Hirachi T; Mizoguchi Y; Monji A; Shimanoe C
Clin Drug Investig; 2024 Feb; 44(2):115-120. PubMed ID: 38135802
[TBL] [Abstract][Full Text] [Related]
17. Amiodarone and Parkinsonism: a pharmacovigilance study.
Montastruc JL; Durrieu G
Fundam Clin Pharmacol; 2021 Aug; 35(4):781-784. PubMed ID: 33098706
[TBL] [Abstract][Full Text] [Related]
18. Metformin, other antidiabetic drugs, and endometrial cancer risk: a nested case-control study within Italian healthcare utilization databases.
Franchi M; Asciutto R; Nicotra F; Merlino L; La Vecchia C; Corrao G; Bosetti C
Eur J Cancer Prev; 2017 May; 26(3):225-231. PubMed ID: 27222938
[TBL] [Abstract][Full Text] [Related]
19. Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database.
Shirani A; Cross AH; Stuve O
Ther Adv Neurol Disord; 2024; 17():17562864241241383. PubMed ID: 38566910
[TBL] [Abstract][Full Text] [Related]
20. Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database.
Alenzi KA; Alsuhaibani D; Batarfi B; Alshammari TM
Front Pharmacol; 2024; 15():1364110. PubMed ID: 38860168
[No Abstract] [Full Text] [Related]
[Next] [New Search]
